MAPK Signaling

Products for MAPK Signaling
- ERK(72)
- MEK1/2(57)
- NKCC(5)
- MNK(5)
- PKA(49)
- p38(88)
- Rac(2)
- Raf(64)
- JNK(54)
- cAMP(32)
- Protein Kinase G(2)
- RSK(28)
- Other(6)
- MAPKAPK(1)
- MKK(2)
- KLF(3)
- MAP3K(18)
- MAP4K(16)
- MAPKAPK2 (MK2)(9)
- Mixed Lineage Kinase(7)
- Cat.No. Product Name Information
-
GN10814
Quercitrin
-
GN10804
Isovitexin
-
GN10784
Rhoifolin
-
GN10752
Pachymic acid
-
GN10709
Polyphyllin A
-
GN10664
Honokiol
-
GN10590
Bakuchiol
-
GN10494
Astragaloside IV
-
GN10481
Corynoxeine
-
GN10409
cor-nuside
-
GN10336
Daphnetin
-
GN10307
Ginsenoside Re
-
GN10267
Loureirin B
-
GN10248
Hesperitin
-
GN10063
Arctigenin
-
GN10023
Isorhamnetin
-
GN10016
Carnosol
-
GC17577
NQDI 1
A selective inhibitor of ASK1
-
GC10282
Piperlongumine
An alkaloid with anticancer and antioxidant activities
-
GC17255
Gliotoxin
An immunosuppressive mycotoxin with diverse biological effects
-
GC11076
XMD8-92
A selective ERK5 inhibitor
-
GC12691
XMD17-109
A selective ERK5 inhibitor
-
GC13115
VX-11e
A selective ERK inhibitor
-
GC15260
Trametinib DMSO solvate
-
GC13578
Skepinone-L
An inhibitor of p38 MAPK
-
GC16001
SCH772984
A selective inhibitor of ERK1/2
-
GC10054
SB 239063
A selective p38 MAPK inhibitor
-
GC14534
Regorafenib monohydrate
A multi-kinase inhibitor
-
GC14606
Regorafenib hydrochloride
A multi-kinase inhibitor
-
GC13514
NG25
An inhibitor of MAP4K2 and TAK1
-
GC11649
MLN 2480
An oral pan-Raf kinase inhibitor
-
GC11277
MEK inhibitor
-
GC13841
JNK-IN-8
A selective, irreversible JNK inhibitor
-
GC15028
JNK-IN-7
A non-selective JNK inhibitor
-
GC14125
FMK
An inhibitor of RSK2
-
GC14114
DB07268
A potent inhibitor of JNK1
-
GC12486
Dabrafenib Mesylate (GSK-2118436)
A Raf kinase inhibitor
-
GC14337
Cobimetinib (R-enantiomer)
-
GC17426
Cobimetinib (racemate)
-
GC10033
Cobimetinib
A potent, orally available MEK1 inhibitor
-
GC14693
CMK
-
GC17860
CEP-32496 hydrochloride
A potent inhibitor of B-Raf
-
GC10446
CC-930
A potent JNK inhibitor
-
GC14197
CC-401 hydrochloride
A potent, specific pan-JNK inhibitor
-
GC12151
B-Raf inhibitor
-
GC12482
BRAF inhibitor
-
GC10918
AT7867 dihydrochloride
A potent and orally bioavailable pan-Akt inhibitor
-
GC12882
AS 602801
A selective, orally bioavailable JNK inhibitor
-
GC13508
Trametinib (GSK1120212)
An inhibitor of MEK1 and MEK2
-
GC14732
PLX-4720
An orally-available inhibitor of the B-raf mutant B-RafV600E
-
GC10397
PD0325901
A MEK inhibitor that sustains stem cell renewal
-
GC17369
Sorafenib
A multi-kinase inhibitor
-
GC13412
Vemurafenib (PLX4032, RG7204)
An inhibitor of mutant V600E and wild type B-Raf
-
GC15299
Staurosporine(CGP 41251)
A potent inhibitor of protein kinase C
-
GP10075
PKA inhibitor fragment (6-22) amide
A synthetic peptide inhibitor of PKA
-
GC25982
Tanzisertib(CC-930)
Tanzisertib (CC-930, JNK-930, JNKI-1) is kinetically competitive with ATP in the JNK-dependent phosphorylation of the protein substrate c-Jun and potent against all isoforms of JNK (Ki(JNK1) = 44 ± 3 nM, IC50(JNK1) = 61 nM, Ki(JNK2) = 6.2 ± 0.6 nM, IC50(JNK2) = 5 nM, IC50(JNK3) = 5 nM) and selective against MAP kinases ERK1 and p38a with IC50 of 0.48 and 3.4 μM respectively.
-
GC25521
IMM-H007
IMM-H007, an adenosine derivative, is an activator of AMP-Activated Protein Kinase (AMPK). IMM-H007 is a potential drug for treating cardiac dysfunction. IMM-H007 negatively regulates endothelium inflammation through inactivating NF-κB and JNK/AP1 signaling. IMM-H007 inhibits ABCA1 (ATP binding cassette subfamily a member 1) degradation and facilitates its cell-surface localization in macrophages, thereby promotes cholesterol efflux.
-
GC25420
Fipexide hydrochloride
Fipexide (hydrochloride) is a psychoactive drug of the piperazine class.
-
GC25289
CompK
CompK (compound K), a potent and selective hematopoietic progenitor kinase 1 (HPK1 or MAP4K1) small molecule inhibitor, significantly improves human T-cell functions, with enhanced T-cell receptor avidity to recognize tumor-associated antigens and tumor cytolytic activity by CD8+ T cells.
-
GC68350
Tinlorafenib
-
GC67964
Exarafenib
-
GC67905
ERK1/2 inhibitor 7
-
GC67800
B-Raf IN 11
-
GC65978
B-Raf IN 10
B-Raf IN 10 (Compound C09) is a BRAF inhibitor with an IC50 between 50 and 100 nM. B-Raf IN 10 shows antitumor activity.
-
GC65949
GNE-9815
GNE-9815 (compound 7) is a highly selective, pan-RAF inhibitor with good oral bioavailability. GNE-9815 exhibits Ki values of 0.062 and 0.19 nM for CRAF and BRAF, respectively. GNE-9815 combines with MEK inhibitor Cobimetinib (HY-13064) shows synergistic modulation of MAPK pathway. GNE-9815 can be used in studies of KRAS mutant cancers.
-
GC65917
Andrograpanin
Andrograpanin, a bioactive compound from Andrographis paniculata, exhibits anti-inflammatory and anti-infectious properties.
-
GC65510
ERK1/2 inhibitor 1
ERK1/2 inhibitor 1 is a potent, orally bioavailable ERK1/2 inhibitor, showing 60% inhibition at 1 nM and an IC50 of 3.0 nM against ERK1 and ERK2, respectively.
-
GC65479
PROTAC B-Raf degrader 1
PROTAC B-Raf degrader 1 (compound 2) is a proteolysis targeting chimera (PROTAC) for the degradation of B-Raf based on Cereblon ligand with anti-cancer activity.
-
GC65329
EW-7195
EW-7195 is a potent and selective ALK5 (TGFβR1) inhibitor with an IC50 of 4.83 nM. EW-7195 has >300-fold selectivity for ALK5 over p38α. EW-7195 efficiently inhibits TGF-β1-induced Smad signaling, epithelial-to-mesenchymal transition (EMT) and breast tumour metastasis to the lung.
-
GC65303
Jaspamycin
Jaspamycin (7-CN-7-C-Ino) is a potent activator of PKA, binding to the R site (PKAR), with an EC50 of 6.5 nM and Kd of 8 nM in Trypanosoma brucei.
-
GC65298
DMX-5804
DMX-5804 is a potent, orally active and selective MAP4K4 inhibitor, with an IC50 of 3 nM, a pIC50 of 8.55 for human MAP4K4, less potent on MINK1/MAP4K6 (pIC50, 8.18), and TNIK/MAP4K7 (pIC50, 7.96).
-
GC65297
MW-150
MW150 (MW01-18-150SRM) is a selective, CNS penetrant, and orally active inhibitor of p38α MAPK with a Ki of 101 nM.
-
GC64904
MAP855
MAP855 is a highly potent, selective, ATP-competitive and orally active MEK1/2 kinase inhibitor (MEK1 ERK2 cascade IC50=3 nM, pERK EC50=5 nM). MAP855 shows equipotent inhibition of wild-type and mutant MEK1/2.
-
GC64828
PLX7922
PLX7922, a RAF inhibitor, can bind with BRAFV600E. PLX7922 inhibits pERK in BRAFV600E cell lines, and activates pERK in mutant NRAS cell lines.
-
GC64634
MLK-IN-1
MLK-IN-1 is a potent, brain penetrant and specific mixed lineage kinase 3 (MLK-3) inhibitor, compound 68, extracted from patent US20140256733A1.
-
GC64580
MMI-0100
MMI-0100 is a cell-permeant peptide inhibitor of mitogen activated protein kinase activated protein kinase II (MK2).
-
GC64550
B-Raf IN 2
B-Raf IN 2 is a potent and selective BRAF inhibitor extracted from patent WO2021116055A1, compound Ia. B-Raf IN 2 can be used for the research of cancer.
-
GC64496
EF24
EF24 is a curcumin analogue with greater anti-tumor efficacy and oral bioavailability via deactivation of the MAPK/ERK signaling pathway in oral squamous cell carcinoma (OSCC). EF24 treatment increases the levels of activated caspase 3 and 9, and decreases the phosphorylated forms of MEK1 and ERK.
-
GC64460
8-Chloro-cAMP
8-Chloro-cAMP is a cAMP analogue that induces growth arrest, and modulates cAMP-dependent PKA activity. 8-Chloro-cAMP has anticancer activity.
-
GC64292
MS432
MS432 is a first-in-class and highly selective PD0325901-based von Hippel-Lindau-recruiting PROTAC degrader for MEK1 and MEK2. MS432 displays good plasma exposure in mice, exhibiting DC50 values of 31 nM and 17 nM for MEK1, MEK2 in HT29 cells respectively.
-
GC64287
SR15006
SR15006 is a inhibitor of Krüppel-like factor 5 (KLF5) with an IC50 of 41.6 nM in DLD-1/pGL4.18hKLF5p cells).
-
GC64035
Hirsutenone
Hirsutenone is an active botanical diarylheptanoid present in Alnus species and exhibits many biological activities, including anti-inflammatory, anti-tumor promoting and anti-atopic dermatitis effects.
-
GC63903
(E)-Osmundacetone
(E)-Osmundacetone is the isomer of Osmundacetone.
-
GC49700
Takeda-6d
-
GC49686
N-desmethyl Regorafenib N-oxide
An active metabolite of regorafenib
-
GP23504
FLRT3 Human
Fibronectin Leucine Rich Transmembrane Protein 3 Human Recombinant
-
GP23419
ESAT6
Early Secretory Target Mycobacterium Tuberculosis Recombinant
-
GC63700
5,6,7-Trimethoxyflavone
5,6,7-Trimethoxyflavone is a novel p38-α MAPK inhibitor with an anti-inflammatory effect.
-
GC63680
MLKL-IN-2
MLKL-IN-2 is a MLKL inhibitor extracted from patent WO2021224505A1, compound (i).
-
GC63569
HPK1-IN-4
HPK1-IN-4 (comp 22) is a HPK1 (MAPK41) inhibitor (IC50 of 0.061 nM) as preclinical immunotherapy tool compound.
-
GC63554
PD0325901-O-C2-dioxolane
PD0325901-O-C2-dioxolane has main portion of MEK inhibitor PD0325901. PD0325901-O-C2-dioxolane and a ligand of VHL or CRBN E3 ligase can be used in the synthesis of MEK1/2 degrader.
-
GC63459
ERK-IN-3 benzenesulfonate
ERK-IN-3 benzenesulfonate is a potent and orally active inhibitor of ERK. ERK-IN-3 benzenesulfonate inhibits ERK1/2 with low single-digit nM IC50 values. ERK-IN-3 benzenesulfonate can be used for the research of cancers driven by RAS mutations.
-
GC63441
CC-99677
CC-99677 is a potent, covalent, and irreversible inhibitor of the mitogen-activated protein (MAP) kinase-activated protein kinase-2 (MK2) pathway in both biochemical (IC50=156.3 nM) and cell based assays (EC50=89 nM).
-
GC63425
Zunsemetinib
Zunsemetinib (CDD-450) is an orally active and selective p38α mitogen-activated protein kinase-activated protein kinase 2 (MK2) pathway inhibitor.
-
GC63317
HPK1-IN-8
HPK1-IN-8 is an allosteric, inactive conformation-selective inhibitor of full-length HPK1.
-
GC63264
Zapnometinib
Zapnometinib (PD0184264), an active metabolite of CI-1040, is a MEK inhibitor, with an IC50 of 5.7 nM.
-
GC63176
Rp-cAMPS sodium salt
Rp-cAMPS sodium salt, a cAMP analog, is a potent, competitive cAMP-induced activation of cAMP-dependent PKA I and II (Kis of 12.5 ?M and 4.5 ?M, respectively) antagonist.
-
GC63144
PF-05381941
PF-05381941 is a potent dual inhibitor of TAK1/p38α, with IC50s of 156 and186 nM, respectively.
-
GC63059
MAP4K4-IN-3
MAP4K4-IN-3 (Compound 17) is a potent and selective MAP4K4 inhibitor with an IC50 of 14.9 nM in kinase assay, an IC50 of 470 nM in cell assay.
-
GC63006
HPK1-IN-7
HPK1-IN-7 is a potent, orally active HPK1 (hematopoietic progenitor kinase 1, MAP4K1) inhibitor (IC50=2.6 nM) with excellent family and kinome selectivity. HPK1-IN-7 shows selectivity against IRAK4 (59 nM) and GLK (140 nM). HPK1-IN-7 shows robust efficacy against MC38 syngeneic tumor model in combination with anti-PD1.